SIRT1 Modulation for Stem Cell Differentiation Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack the ability to effectively control the differentiation of embryonic stem cells into adipocytes or kidney precursor cells, with SIRT1's role in this process not fully understood or regulated.
Innovation Solution
Regulating the expression of SIRT1 in embryonic stem cells using inhibitors or promoters, such as Sirtinol, Nicotinamide, and resveratrol, to inhibit or promote differentiation into adipocytes or kidney precursor cells by manipulating mRNA expressions of PPAR-γ, C/EBP α, FABP4, SIX2, and WT1.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If SIRT1 expression is inhibited in embryonic stem cells, then differentiation into adipocytes is inhibited, but differentiation into kidney precursor cells is also inhibited
Solution Approach 1:
The patent applies preliminary action by treating embryonic stem cells with SIRT1 expression inhibitors at specific early time points during differentiation (e.g., days 0-3 or 0-5 of adipogenic differentiation). This timing-specific intervention allows selective inhibition of adipocyte differentiation while preserving kidney precursor cell differentiation potential, resolving the contradiction between precision control and pathway flexibility
Solution Approach 2:
The patent implements dynamics by adjusting the duration and timing of SIRT1 inhibitor treatment based on the desired differentiation outcome. Shorter treatment periods (0-3 days) favor kidney precursor differentiation, while longer periods (0-7 days) enhance adipocyte differentiation inhibition. This dynamic control strategy enables precise manipulation of differentiation pathways while maintaining cellular adaptability
2Productivity
If SIRT1 expression is promoted in embryonic stem cells, then differentiation into kidney precursor cells is promoted, but differentiation into adipocytes is also promoted
Solution Approach 1:
The patent applies periodic action by using pulsed or intermittent treatment with SIRT1 modulators rather than continuous exposure. This periodic intervention, combined with specific differentiation induction media changes at defined time points, enables selective enhancement of kidney precursor differentiation while suppressing adipocyte differentiation, thereby achieving both high productivity and pathway specificity
Solution Approach 2:
The patent utilizes parameter changes by adjusting the concentration and timing of SIRT1 modulator application. Low concentrations of SIRT1 promoters applied during specific windows (e.g., days 0-5 of differentiation) enhance kidney precursor formation, while higher concentrations or different timing patterns suppress adipocyte differentiation. This parameter optimization resolves the contradiction between differentiation efficiency and pathway specificity
3Manufacturing precision
If SIRT1 expression is regulated at early stages of embryoid body formation, then differentiation control is enhanced, but cell proliferation may be affected
Solution Approach 1:
The patent applies partial action by using sub-toxic concentrations of SIRT1 modulators that are sufficient to influence differentiation gene expression (PPAR-γ, C/EBPα, SIX2, WT1) but do not compromise cell viability. This partial intervention approach allows precise differentiation timing control while maintaining reliable cell survival and proliferation during embryoid body formation
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method allows for controlled differentiation of embryonic stem cells into adipocytes or kidney precursor cells, providing a model for studying obesity and kidney disease, and potentially serving as therapeutic agents for metabolic and kidney-related disorders.
Implementation Method 1
SIRT1 is a NAD+ dependent deacetylase that is known to be an enzyme that regulates protein function by deacetylating lysine residues of various proteins
Implementation Method 2
SIRT1 reconstitutes chromatin through histone deacetylation, inhibits gene expression
Data Source
AI summary
The present disclosure relates to a method for controlling the differentiation of embryonic stem cells into adipocytes or kidney precursor cells by regulating SIRT1 (silent mating type information regulation 2 homolog; sirtuin 1) expression, the method, which controls the differentiation of embryonic stem cells into adipocytes by regulating SIRT1 expression, being capable of controlling the inhibition or promotion of adipocyte differentiation in accordance with the timing of a SIRT1 expression inhibitor treatment. Furthermore, kidney precursor cell differentiation can be regulated by a SIRT1 expression inhibitor or promoter treatment. Accordingly, a SIRT1 inhibitor can be selected to be used as an inhibitor or a therapeutic agent for obesity, diabetes accompanying obesity, and renal and metabolic diseases.